Skip to content
Lavo Life Sciences logo

Lavo Life Sciences

Lavo Life Sciences is a YC Winter 2023 (W23) company. Team of 3.

  • AI-powered Drug Discovery
  • Machine Learning
  • Biotech
  • Drug discovery

About Lavo Life Sciences

GPAgent's own fund-neutral profile, written from public information. Updated Oct 5, 2026.

Summary

Lavo Life Sciences builds AI-driven simulation software that models drug molecule behavior computationally. Pharmaceutical companies use these simulations to inform formulation decisions before running physical experiments, cutting lab time and reducing trial-and-error in development. The work the platform replaces is costly, slow bench experimentation that traditionally precedes clinical trials and regulatory submission.

Go-to-market

Pharmaceutical and biotech companies are the buyers, engaging Lavo Life Sciences to integrate computational simulations into their drug formulation workflows.

From the Y Combinator listing

How Lavo Life Sciences describes itself in Y Combinator's public directory. Original listing (opens in a new tab)

AI for drug formulation

Lavo Life Sciences runs simulations of drug molecules on computers. Pharma companies use these simulations to guide their experiments and ultimately save time and money in the lab. This will de-risk and expedite clinical trials and FDA approval.

Facts

Industry
Healthcare / Healthcare -> Drug Discovery and Delivery
Team size
3
Status
Inactive
Stage
Early

Founders (3)

Score every batch against your own thesis

GPAgent's sourcing agent reads every company in a batch, scores each one against your fund's thesis in a private workspace, and lines up the founders worth meeting before Demo Day. You decide who to contact. Your scores, notes, and pipeline never appear on these pages.

How Accelerator intelligence works